CClinicalTrials.gg
CompletedNCT04424745TANDEMUpdated Jan 22, 2025

Neuromodulation with Attention Bias Modification Training for Binge Eating Disorder

An interventional study of Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS) in Binge-Eating Disorder, sponsored by King's College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by King's College London · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Binge eating disorder (BED) is a common and disabling eating disorder (ED) which has significant effects on psychological wellbeing, physical health, and quality of life. Talking therapies, most notably cognitive behaviour therapy (CBT), are presently recommended for the treatment of BED. However, outcomes from treatment are inadequate. Therefore, there is a need for development of new treatments.

This study aims to investigate the feasibility of combining Attention Bias Modification Training (ABMT) and Transcranial Direct Current Stimulation (tDCS) to reduce binge-eating behaviour and craving for food in people with BED.

ABMT is a computerised training that seeks to alter responses towards food that people are not consciously aware of. During ABMT, participants are trained to 'look towards' low-calorie food and 'look away' from high-calorie food. TDCS is a safe, well tolerated, non-invasive form of brain stimulation which is suitable for supervised self-administration. It stimulates specific brain areas using a mild electrical current (2 mA) via small electrodes placed on the scalp. In this study, participants will be randomly allocated to receive either ABMT with real tDCS or ABMT with sham tDCS. ABMT and real/sham tDCS will be delivered simultaneously, i.e. participants will engage in ABM training whilst receiving tDCS. All participants will be remotely supervised by the study researcher for the duration of each treatment session.

Biological male and female adults (aged 18-60) of any gender will be eligible to take part if they have a DSM-V of BED and they are overweight or obese.

Taking part will involve completing 10 sessions of combined ABMT and real or sham tDCS over 2-3 weeks. Binge frequency, food craving and other outcomes will be measured at the start of the study, end of the study, and at the 6-week follow-up.

02

Conditions studied

03

In context

Bulimia

319 studies on the registry are indexed under Bulimia; 53 are open to participants now.

This study's enrollment of 84 is above the median of 61 across 249 interventional studies indexed under Bulimia.

Browse Bulimia studies →

Lead sponsor

King's College London is the lead sponsor of 506 studies on the registry; 125 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Overweight or obese according to WHO criteria (BMI>25 kg/m²)
  • Meet criteria for full-syndrome DSM-5 Binge Eating Disorder (BED)
  • Right-handed
  • Must use and understand English as a language for everyday conversation
  • Access to a laptop or desktop computer with webcam

Exclusion criteria

Exclusion Criteria:

  • Visual impairments that cannot be corrected with contact lenses or glasses
  • Pregnancy
  • History of neurological disease and/or seizure
  • Having any metallic implants anywhere in the head or body
  • History of head or eye injury
  • Significant health problems in the previous six months
  • Lifetime diagnosis of substance dependence, psychosis, bipolar disorder, borderline personality disorder
  • Other primary psychiatric disorder requiring treatment in its own right
  • Taking psychotropic medication other than a stable dosage of selective serotonin reuptake inhibitors (SSRI) for at least 14 days prior to study enrollment
  • Adults consuming more than 14 units of alcohol per week who are unwilling to reduce their alcohol intake for the duration of the treatment.
  • Current illicit drug use.
  • Learning difficulties that would preclude safe tDCS self-administration and/or completion of questionnaire measures and neurocognitive tasks.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
84 participants (actual)

Study arms

  • Active comparator
    Attention Bias Modification Training with real tDCS

    Other: Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)

  • Placebo comparator
    Attention Bias Modification Training with sham tDCS

    Other: Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)

Interventions

  • OtherSimultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)

    Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.

06

What researchers measure

Primary outcomes

  1. Achievement of a 'steady state' of recruitment

    Recruitment rate/month over months will be assessed to demonstrate that recruitment targets for the main trial can be met within an adequate time-frame. An average of 3 patients per month must be recruited (randomised) over a consecutive 12 month period (a minimum of 36 patients) in order to demonstrate a 'steady state' of recruitment.

    Time frame: Start of Recruitment to 12 months

Secondary outcomes

  1. Eating Disorder Symptoms

    The Eating Disorder Examination Questionnaire (EDE-Q) will be used to assess eating disorders symptoms. The EDE-Q is a 36-item self-report quesitonnaire, and a higher global score indicates more severe eating disorder symptoms.

    Time frame: Baseline to 6 week follow up (on average, 8 weeks after baseline assessment)

  2. Craving for food

    The Food Craving Questionnaire (FCQ) will be used to assess trait-level craving for food. Total scores can range between 15 and 90, with higher scores indicating more frequent and intense food cravings.

    Time frame: Baseline to 6 week follow up (on average, 8 weeks after baseline assessment)

  3. General psychopathology

    The Depression, Anxiety and Stress- Scale (DASS-21) is a 21-item self-report questionnaire which aims to evaluate mood, anxiety and stress levels over the previous week. Sum scores for the total DASS range between 0 and 120, with higher scores indicating more severe psychopathology. Sub-scales assess depression, anxiety and stress symptoms specifically, and scores range from 0 to 42, with higher scores indicating more severe symptoms.

    Time frame: Baseline to 6 week follow up (on average, 8 weeks after baseline assessment)

  4. Physical Health

    Weight and height will be combined to report body mass index in kg/m\^2

    Time frame: Baseline to 6 week follow up (on average, 8 weeks after baseline assessment)

  5. Food related attention

    The Food Attention Network Task (Food-ANT) will be used to assess three components of attention (i.e. orienting, alerting and executive function) using food (low- and high-calorie) versus non-food pictures (neutral items). Change in reaction time will be used to assess change in orienting, alerting and executive function.

    Time frame: Baseline to 6 week follow up (on average, 8 weeks after baseline assessment)

  6. Attention Bias for Food

    The Visual Probe Task (VP) will be used to assess visuo-spatial attention biases for food cues. Change in dwell time measured by eye tracking and reaction time will be used to assess change in attention bias for food cues.

    Time frame: Baseline to 6 week follow up (on average, 8 weeks after baseline assessment)

  7. Working Memory

    Participants are presented with a continuous stream of stimuli (either faces or words), and for every stimulus, the participant must indicate (yes/no) whether or not the current stimulus is the same as the one presented three trials back. This is known as the N-Back and is a measure of working memory. Higher numbers of correct responses indicates superior working memory function.

    Time frame: Baseline to post treatment (on average 18 days after baseline assessment)

  8. Face Affective Go/No Go

    Neuropsychological task measuring information processing biases for positive and negative facial expressions. The participant is told a target emotion and asked to press a button only when the target emotion is present. The task consists of six blocks, each of which presents a series of faces showing either the target emotion or a differently valenced distractor. Reaction times are calculated for correct responses for each condition. Affective bias scores are calculated by subtracting the sad target/happy distractor condition reaction time from the happy target/sad distractor condition reaction time.

    Time frame: Baseline to post treatment (on average 18 days after baseline assessment)

  9. Cognitive Flexibility

    In Wisconsin Card Sorting Test (WCST) participants are asked to sort 64 cards to match either color (red, blue, yellow, or green), form (crosses, circles, triangles, or stars), or number of figures (one, two, three, four). During the task, the sorting rule changes discreetly from color to form or number of figures without the participants being informed. The participants have to shift sets accordingly and sort cards following the new sorting rule. Set shifting difficulties are indicated by preservative errors; thus, higher scores on this test represent poorer cognitive flexibility.

    Time frame: Baseline to post treatment (on average 18 days after baseline assessment)

07

Study locations

1 site
  • King's College London
    London, SE58AF, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04424745
Lead sponsor
King's College London
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Feb 25, 2021
Primary completion
Jan 31, 2022
Completion
Sep 30, 2022
Last update
Jan 22, 2025

Study contacts

Ulrike Schmidt, MD PhD
principal investigator · King's College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion